2022 / 06

Next Paper
DOI: 10.24075/brsmu.2022.073

ORIGINAL RESEARCH

Amicoumacin-based prodrug development approach

Shmygarev VI1, Prokopenko YuA1, Terekhov SS1, Zakharova MYu1, Dubinny MA1, Smirnov IV1, Yampolsky IV1,2, Tsarkova AS1,2
About authors

1 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia

2 Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Alexandra Sergeevna Tsarkova
st. Miklukho-Maklaya, 16/10, Moscow, 117997, Russia; moc.liamg@avokrastla

About paper

Funding: the work was supported by the grant № 075-15-2021-1049 from the Ministry of Science and Higher Education of the Russian Federation.

Contribution of the authors: Yu. A. Prokopenko — development and isolation of Amikoumacin; V. I. Shmygarev — complete synthesis of an inactivated analog of Amikoumacin A; S. S. Terekhov, M. Yu. Zakharova — in vitro experiments with MPro protease; M. A. Dubinny — NMR spectroscopy and data analysis; A. S. Tsarkova — literature analysis, data processing, article writing; I. V. Yampolsky, I. V. Smirnov - general project management.

Compliance with ethical standards: the work was carried out in compliance with the principles of the Declaration of Helsinki of the World Medical Association.

Received: 2022-11-15 Accepted: 2022-12-18 Published online: 2022-12-30
|
  1. Kolahchi Z, De Domenico M, Uddin LQ, Cauda V, Grossmann I, Lacasa L, et al. COVID-19 and Its Global Economic Impact. Adv Exp Med Biol. 2021; 1318: 825‒37.
  2. Marabotti C. Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. Expert Rev Vaccines. 2022; 21 (7): 873‒75.
  3. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. The Lancet Microbe. 2021; 2 (7): e279‒e280.
  4. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021; 397 (10269): 72‒74.
  5. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021; 397 (10275): 642‒3.
  6. Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021; 374: 1586‒93.
  7. de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O’Connor R, et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol. 2021; 95 (10): e01819‒20.
  8. Saban M, Kaim A, Myers V, Wilf-Miron R. COVID-19 Vaccination, Morbidity, and Mortality During a 12-Month Period in Israel: Can We Maintain a “Herd Immunity” State? Popul Health Manag. 2022; 25 (5): 684.
  9. Stepanova M, Lam B, Younossi E, Felix S, Ziayee M, Price J, et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infect Dis. 2022; 22: 702.
  10. Itoh J, Omoto S, Shomura T, Nishizawa N, Miyado S, Yuda Y, et al. Amicoumacin-A, a new antibiotic with strong antiinflammatory and antiulcer activity. J Antibiot (Tokyo). 1981; 34 (5): 611‒3.
  11. Terexov SS, Mokrushina YuA, Smirnov IV, Gabibov AG. Shtamm Bacillus pumilus, produciruyushhij antibiotik shirokogo spektra dejstviya. RU2737856C1, 2020. Dostupno po ssylke: https://patents.google.com/patent/RU2737856C1/en?oq=RU2737856C1. Russian.
  12. Terekhov SS, Smirnov IV, Malakhova MV, Samoilov AE, Manolo AI, Nazarov AS, et al. Ultrahigh-throughput functional profiling of microbiota communities. Proc Natl Acad Sci U S A. 2018; 115 (38): 9551‒6.
  13. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020; 368 (6489): 409‒12.
  14. Zakharova MY, Kuznetsova AA, Uvarova VI, Fomina AD, Kozlovskaya LI, Kaliberda EN, et al. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. Front Pharmacol. 2021; 12: 3243.
  15. Baranova MN, Kudzhaev AM, Mokrushina YA, Babenko VV, Kornienko MA, Malakhova MV, et al. Deep Functional Profiling of Wild Animal Microbiomes Reveals Probiotic Bacillus pumilus Strains with a Common Biosynthetic Fingerprint. Int J Mol Sci. 2022; 23 (3): 1168.
  16. Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, et al. Feline coronavirus drug inhibits
  17. Schädel N, Icik E, Martini M, Altevogt L, Ramming I, Greulich A, et al. Synthesis of Imidazole and Histidine-Derived Cross-Linkers as Analogues of GOLD and Desmosine. Synthesis (Stuttg). 2021; 53 (13): 2260‒8.
  18. Mou K, Xu B, Ma C, Yang X, Zou X, Lü Y, et al. Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors. Bioorg Med Chem Lett. 2008; 18 (6): 2198‒202.
  19. Prokhorova IV, Akulich KA, Makeeva DS, Osterman IA, Skvortsov DA, Sergiev PV, et al. Amicoumacin A induces cancer cell death by targeting the eukaryotic ribosome. Sci Rep. 2016; 6: 27720.
  20. Maksimova EM, Vinogradova DS, Osterman IA, Kasatsky PS, Nikonov OS, Milón P, et al. Multifaceted Mechanism of Amicoumacin A Inhibition of Bacterial Translation. Front Microbiol. 2021; 12: 618857.
  21. Terekhov SS, Nazarov AS, Mokrushina YA, Baranova MN, Potapova NA, Malakhova MV, et al. Deep functional profiling facilitates the evaluation of the antibacterial potential of the antibiotic amicoumacin. Antibiotics. 2020; 9: 157.
  22. Terekhov SS, Mokrushina YA, Nazarov AS, Zlobin A, Zalevsky A, Bourenkov G, et al. A kinase bioscavenger provides antibiotic resistance by extremely tight substrate binding. Sci Adv. 2020; 6 (26): eaaz9861.
  23. Therapeutics and COVID-19: living guideline, Geneva: World Health Organization c2022 [cited 2022 Dec 19]. Available from: https://app.magicapp.org/#/guideline/nBkO1E/section/nYlJyL.